We are live on
!
Find out more
SCM
Soleus Capital Management Portfolio holdings
AUM
$2.9B
1-Year Est. Return
169.69%
This Fund
S&P 500
This Quarter
Est. Return
-13.52%
1 Year Est. Return
+169.69%
3 Year Est. Return
+507.65%
5 Year Est. Return
+746.04%
10 Year Est. Return
–
AUM
$641M
AUM Growth
-$134M
(-17%)
Cap. Flow
+$78.2M
Cap. Flow
% of AUM
12.2%
Top 10 Holdings %
Top 10 Hldgs %
43.19%
Holding
88
New
23
Increased
22
Reduced
22
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SkinHealth Systems
SKIN
|
+$40.8M |
| 2 |
Organogenesis Holdings
ORGO
|
+$16.9M |
| 3 |
Tandem Diabetes Care
TNDM
|
+$15.1M |
| 4 |
AnaptysBio
ANAB
|
+$14.3M |
| 5 |
CUTR
Cutera, Inc.
CUTR
|
+$13.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Illumina
ILMN
|
+$21.8M |
| 2 |
OraSure Technologies
OSUR
|
+$20.7M |
| 3 |
HOLX
Hologic
HOLX
|
+$17.3M |
| 4 |
Smith & Nephew
SNN
|
+$12.3M |
| 5 |
10x Genomics
TXG
|
+$8.07M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.81% |
| 2 | Consumer Staples | 6.57% |
| 3 | Miscellaneous | 5.54% |
| 4 | Financials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
United Therapeutics
UTHR
$21.5B
| $69.6M | 10.86% |
295,541
-10,309
| -3% | -$2.1M |
|
|
2
SkinHealth Systems
SKIN
$87.8M
| $42.1M | 6.57% |
3,276,037
+3,048,425
| +1,339% | +$40.8M |
|
|
3
Organogenesis Holdings
ORGO
$188M
| $25.8M | 4.02% |
5,286,167
+2,746,000
| +108% | +$16.9M |
|
|
SRDX
4
DELISTED
Surmodics
SRDX
| $24.6M | 3.84% |
661,004
+102,564
| +18% | +$3.98M |
|
|
FOCL
5
EDAP TMS S.A.
FOCL
$187M
| $22.3M | 3.48% |
3,284,189
+135,580
| +4% | +$940K |
|
6
iRadimed
IRMD
$1.05B
| $21.1M | 3.29% |
620,765
+190,714
| +44% | +$6.84M |
|
7
CVS Health
CVS
$121B
| $20.3M | 3.17% |
219,400
+126,900
| +137% | +$12.4M |
|
|
THER
8
DELISTED
THERATECHNOLOGIES INC COM
THER
| $17.8M | 2.77% |
7,822,412
+130,330
| +2% | +$296K |
|
|
9
CALL
SkinHealth Systems
SKIN
$87.8M
| $16.7M | 2.61% |
+1,300,000
| New | +$17.4M |
|
|
ACLX
10
DELISTED
Arcellx
ACLX
| $16.4M | 2.57% |
909,739
-80,000
| -8% | -$1.03M |
|
11
Inspire Medical Systems
INSP
$2.16B
| $16.2M | 2.53% |
88,950
+41,050
| +86% | +$8.19M |
|
12
Krystal Biotech
KRYS
$9.97B
| $14.1M | 2.2% |
214,482
-74,855
| -26% | -$4.66M |
|
|
EPIX
13
DELISTED
ESSA Pharma
EPIX
| $13.1M | 2.05% |
4,168,799
-55,000
| -1% | -$307K |
|
|
14
AnaptysBio
ANAB
$1.62B
| $13.1M | 2.04% |
+643,575
| New | +$14.3M |
|
15
AngioDynamics
ANGO
$648M
| $13M | 2.02% |
670,000
-356,450
| -35% | -$7.3M |
|
|
DICE
16
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $12.7M | 1.98% |
815,740
-168,254
| -17% | -$2.89M |
|
17
Nurix Therapeutics
NRIX
$2.58B
| $12.6M | 1.97% |
994,492
-17,146
| -2% | -$194K |
|
|
APEN
18
DELISTED
Apollo Endosurgery, Inc.
APEN
| $11.9M | 1.86% |
3,268,948
+375,848
| +13% | +$1.78M |
|
19
Neuropace
NPCE
$489M
| $11.6M | 1.8% |
2,334,003
+10,000
| +0.4% | +$66K |
|
20
AstraZeneca
AZN
$251B
| $11.2M | 1.75% |
84,848
+28,500
| +51% | +$3.74M |
|
|
21
Tandem Diabetes Care
TNDM
$1.13B
| $10.9M | 1.7% |
+183,800
| New | +$15.1M |
|
22
Viridian Therapeutics
VRDN
$2.47B
| $9.73M | 1.52% |
841,018
+751,018
| +834% | +$10.1M |
|
|
CUTR
23
DELISTED
Cutera, Inc.
CUTR
| $9.66M | 1.51% |
+257,600
| New | +$13.6M |
|
24
Evolus
EOLS
$522M
| $9.4M | 1.47% |
810,676
-557,713
| -41% | -$6.58M |
|
|
BCAB
25
DELISTED
BIOATLA INC
BCAB
| $9.3M | 1.45% |
65,254
+14,946
| +30% | +$2.38M |
|
Similar funds
GA
LSA
7WCP
ACM
HWA
JC
WPW
BWL
Soleus Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, Soleus Capital Management held 88 positions worth $641M, down 17% from $775M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Soleus Capital Management deployed $78.2M of net new capital in Q2 2022, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was Tandem Diabetes Care: 183,800 shares worth $10.9M.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 80% a quarter earlier, followed by Consumer Staples and Miscellaneous.
On the sell side, the largest reduction was Kyntra Bio, an estimated $7.79M trimmed.
- Soleus Capital Management's largest Q2 2022 buy was Tandem Diabetes Care: 183,800 shares worth $10.9M.
- Soleus Capital Management added most to SkinHealth Systems in Q2 2022, an estimated $40.8M increase.
- Soleus Capital Management's biggest Q2 2022 reduction was Kyntra Bio, cutting an estimated $7.79M.
- Soleus Capital Management fully exited Illumina in Q2 2022, selling an estimated $21.8M.
- Soleus Capital Management's ten largest holdings make up 43% of its $641M portfolio in Q2 2022.
- Soleus Capital Management opened 23 new positions and closed 16 in Q2 2022.
- Soleus Capital Management's portfolio value fell 17% quarter-over-quarter to $641M.
Based on Soleus Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.